deltatrials
Terminated PHASE2 INTERVENTIONAL 3-arm NCT03292653

Safety, Tolerability and Pharmacodynamic Activity of Sotagliflozin in Hemodynamically Stable Participants With Worsening Heart Failure

An Exploratory, Randomized, Double-blind, Placebo-controlled, Parallel Arm Trial of the Safety and Pharmacodynamic Activity of Sotagliflozin in Hemodynamically Stable Patients Hospitalized With Worsening Heart Failure

Sponsor: Lexicon Pharmaceuticals

Updated 25 times since 2017 Last updated: Apr 16, 2021 Started: Dec 4, 2017 Primary completion: Aug 17, 2019 Completion: Aug 17, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

1st two cohorts provided the required data, therefore 3rd cohort was not deemed necessary

This PHASE2 trial investigates Cardiac Failure Aggravated and is currently terminated or withdrawn. Lexicon Pharmaceuticals leads this study, which shows 25 recorded versions since 2017 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

~Oct 2017 – ~Dec 2017 · 2 months · monthly snapshot~Dec 2017 – ~Feb 2018 · 2 months · monthly snapshot~Feb 2018 – ~Mar 2018 · 28 days · monthly snapshot~Mar 2018 – ~Apr 2018 · 31 days · monthly snapshot~Apr 2018 – ~May 2018 · 30 days · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Apr 2019 · 4 months · monthly snapshot~Apr 2019 – ~Jul 2019 · 3 months · monthly snapshot~Jul 2019 – ~Oct 2019 · 3 months · monthly snapshot~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Jan 2020 · 2 months · monthly snapshot~Jan 2020 – ~Mar 2020 · 2 months · monthly snapshot~Mar 2020 – ~Jun 2020 · 3 months · monthly snapshot~Jun 2020 – ~Sep 2020 · 3 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Jun 2021 · 5 months · monthly snapshot~Jun 2021 – ~Jul 2024 · 37 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 23 months · monthly snapshot

Change History

25 versions recorded
  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Jun 2021 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Jan 2021 — Jun 2021 [monthly]

    Terminated PHASE2

  5. Sep 2020 — Jan 2021 [monthly]

    Terminated PHASE2

Show 20 earlier versions
  1. Jun 2020 — Sep 2020 [monthly]

    Terminated PHASE2

    Status: SuspendedTerminated

  2. Mar 2020 — Jun 2020 [monthly]

    Suspended PHASE2

  3. Jan 2020 — Mar 2020 [monthly]

    Suspended PHASE2

    Status: RecruitingSuspended

  4. Nov 2019 — Jan 2020 [monthly]

    Recruiting PHASE2

  5. Oct 2019 — Nov 2019 [monthly]

    Recruiting PHASE2

  6. Jul 2019 — Oct 2019 [monthly]

    Recruiting PHASE2

  7. Apr 2019 — Jul 2019 [monthly]

    Recruiting PHASE2

  8. Dec 2018 — Apr 2019 [monthly]

    Recruiting PHASE2

  9. Nov 2018 — Dec 2018 [monthly]

    Recruiting PHASE2

  10. Oct 2018 — Nov 2018 [monthly]

    Recruiting PHASE2

  11. Sep 2018 — Oct 2018 [monthly]

    Recruiting PHASE2

  12. Aug 2018 — Sep 2018 [monthly]

    Recruiting PHASE2

  13. Jul 2018 — Aug 2018 [monthly]

    Recruiting PHASE2

  14. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE2

  15. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

  16. Apr 2018 — May 2018 [monthly]

    Recruiting PHASE2

  17. Mar 2018 — Apr 2018 [monthly]

    Recruiting PHASE2

  18. Feb 2018 — Mar 2018 [monthly]

    Recruiting PHASE2

  19. Dec 2017 — Feb 2018 [monthly]

    Recruiting PHASE2

    Status: Not Yet RecruitingRecruiting

  20. Oct 2017 — Dec 2017 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Lexicon Pharmaceuticals
  • Sanofi
Data source: Lexicon Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .